Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191, a Novel CD19 Targeted Allogeneic CGlobeNewsWire • 12/09/19
Precision BioSciences, Inc. (DTIL) Shares March Higher, Can It Continue?Zacks Investment Research • 11/27/19
Precision BioSciences Welcomes Healthcare Industry Expert, Kevin J. Buehler, to its Board of DirectorsGlobeNewsWire • 11/13/19